MAP1B Polypeptide Detection of PCA-2 Autoantibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective detection and treatment strategies for paraneoplastic neurological disorders and cancers associated with PCA-2-specific autoantibodies, which are biomarkers for conditions like small-cell lung carcinoma, as they often result in diverse neurological manifestations and require precise diagnostic and therapeutic interventions.
Innovation Solution
The use of microtubule-associated protein 1B (MAP1B) polypeptides and fragments, which serve as antigens to detect PCA-2-specific autoantibodies in biological samples, facilitating diagnosis and treatment by forming complexes that can be detected through methods like Western blot, and providing a basis for immunotherapy targeting these autoantibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current detection methods are used for PCA-2-specific autoantibodies, then diagnostic capability is limited, but implementation complexity remains manageable
Solution Approach 1:
The patent introduces MAP1B polypeptides as intermediary antigens that specifically bind to PCA-2-specific autoantibodies. This intermediary approach enables accurate detection of the autoantibodies through Western blot analysis, transforming an undetectable condition into a measurable complex formation between MAP1B and PCA-2-specific autoantibodies in patient samples
Solution Approach 2:
The patent employs preliminary action by preparing specific MAP1B polypeptide sequences (including amino acid sequences 1-2803, 1-2120, 1-1690, or fragments thereof) in advance as detection reagents. These pre-prepared polypeptides are designed with specific epitopic sites that will bind to PCA-2-specific autoantibodies, allowing the detection method to be readily applied when diagnostic testing is needed
2Adaptability or versatility
If diverse neurological manifestations are considered in diagnosis, then diagnostic coverage is improved, but diagnostic difficulty increases
Solution Approach 1:
The patent establishes a universal diagnostic approach using MAP1B polypeptides that can detect PCA-2-specific autoantibodies across multiple neurological conditions. The same detection method applies to paraneoplastic neurological disorders, cerebellar degeneration, encephalitis, and other neurological manifestations, providing a multi-functional diagnostic tool that covers diverse conditions without requiring condition-specific tests
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate diagnosis and treatment of paraneoplastic neurological disorders and cancers by specifically targeting PCA-2-specific autoantibodies, potentially reducing symptoms and improving patient outcomes by addressing the underlying autoimmune response.
Implementation Method 1
contacting a biological sample from an individual with a MAP1B polypeptide or fragment thereof including one or more epitopic sites to form a MAP1B-PCA-2-specific autoantibody complex if the biological sample contains said PCA-2-specific autoantibody
Data Source
Figure 1A~1F
Figure 2A~2B
Figure 3AA~3BE
AI summary
This document provides methods and materials for detecting PCA-2-specific autoantibodies, which can be associated with paraneoplastic neurological disorders and cancers associated with PCA-2-specific autoantibodies.